MCID: GRD007
MIFTS: 60

Grade Iii Astrocytoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Grade Iii Astrocytoma

MalaCards integrated aliases for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma 12 53 15
Anaplastic Astrocytoma 12 53 59 55 73
Grade Iii Astrocytic Tumor 12
Astrocytoma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

59
anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3078
MeSH 44 D001254
NCIt 50 C9477
SNOMED-CT 68 55353007
Orphanet 59 ORPHA251589
UMLS via Orphanet 74 C0334579
ICD10 via Orphanet 34 C71.9
UMLS 73 C0334579

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : 53 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy.

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to glioblastoma and frontal convexity meningioma, and has symptoms including headache, seizures and motor manifestations. An important gene associated with Grade Iii Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Temodar and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are Decreased viability in esophageal squamous lineage and Reduced mammosphere formation

Disease Ontology : 12 An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 glioblastoma 26.3 CDK4 CDKN2A CDKN2B DMBT1 EGFR IDH2
2 frontal convexity meningioma 11.0 GFAP TP53
3 brain ependymoma 10.9 EGFR TP53
4 gliofibroma 10.9 GFAP TP53
5 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
6 intracranial chondrosarcoma 10.9 IDH2 TP53
7 zika virus infection 10.9 MDM2 TP53
8 protoplasmic astrocytoma 10.8 GFAP IDH2 TP53
9 cerebral convexity meningioma 10.8 GFAP TP53
10 oligoastrocytoma 10.8 GFAP IDH2 MGMT
11 oral leukoplakia 10.8 CDKN2A PCNA TP53
12 suppressor of tumorigenicity 3 10.8 CDKN2A PCNA TP53
13 anal squamous cell carcinoma 10.8 CDKN2A MGMT TP53
14 pleomorphic xanthoastrocytoma 10.8 GFAP MGMT TP53
15 gemistocytic astrocytoma 10.8 GFAP IDH2 PTEN
16 inverted papilloma 10.8 CDKN2A PCNA TP53
17 oropharynx cancer 10.7 CDKN2A EGFR TP53
18 cellular ependymoma 10.7 GFAP TP53
19 basaloid squamous cell carcinoma 10.7 CDKN2A EGFR TP53
20 vulva cancer 10.7 CDKN2A EGFR TP53
21 pre-malignant neoplasm 10.7 CDKN2A EGFR TP53
22 ring chromosome 7 10.7 CDK4 MDM2 TP53
23 necrotizing sialometaplasia 10.7 CDKN2A GFAP TP53
24 mucinous stomach adenocarcinoma 10.7 PTEN VEGFA
25 gastric lymphoma 10.7 PCNA TP53 VEGFA
26 penile cancer 10.7 CDKN2A EGFR TP53
27 central nervous system lymphoma 10.7 CDKN2A MGMT TP53
28 juvenile pilocytic astrocytoma 10.7 CDKN2A GFAP TP53
29 in situ carcinoma 10.7 CDKN2A EGFR TP53
30 bladder squamous cell carcinoma 10.7 CDKN2A PTEN TP53
31 adult medulloblastoma 10.7 GFAP MDM2 TP53
32 periosteal osteogenic sarcoma 10.7 CDK4 MDM2 TP53
33 actinic cheilitis 10.7 MDM2 TP53
34 anaplastic ependymoma 10.7 GFAP MDM2 PTEN
35 cervical adenocarcinoma 10.7 CDKN2A EGFR TP53
36 small cell sarcoma 10.6 CDK4 MDM2 TP53
37 ependymoma 10.6 EGFR GFAP MGMT
38 primary peritoneal carcinoma 10.6 EGFR TP53 VEGFA
39 cellular schwannoma 10.6 CDKN2A MDM2 TP53
40 embryonal sarcoma 10.6 CDK4 MDM2 TP53
41 thyroid lymphoma 10.6 CDKN2A CDKN2B TP53
42 scrotal carcinoma 10.6 CDKN2A CDKN2B TP53
43 inflammatory mfh 10.6 CDK4 GFAP MDM2
44 malignant peritoneal mesothelioma 10.6 CDKN2A EGFR
45 intrahepatic cholangiocarcinoma 10.6 EGFR IDH2 TP53
46 malignant mesenchymoma 10.6 CDK4 MDM2 TP53
47 ischemic fasciitis 10.6 CDK4 CDKN2A MDM2
48 preretinal fibrosis 10.6 GFAP VEGFA
49 breast carcinoma in situ 10.6 EGFR TP53 VEGFA
50 atypical lipomatous tumor 10.6 CDK4 CDKN2A MDM2

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:



Diseases related to Grade Iii Astrocytoma

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:


headache, seizures, motor manifestations, sensory manifestations

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.7 IDH2 MMP2 OLIG1 PDGFRA PTEN TP53
2 Reduced mammosphere formation GR00396-S 9.17 IDH2 MDM2 MMP2 PCNA PTEN CDK4

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.49 VEGFA TP53 CDK4 APOD BSG CDKN2A
2 growth/size/body region MP:0005378 10.46 VEGFA TP53 PTEN BSG CDKN2A CDK4
3 homeostasis/metabolism MP:0005376 10.44 TP53 PTEN CDKN2A CDK4 APOD VEGFA
4 cardiovascular system MP:0005385 10.43 TP53 PTEN VEGFA CDKN2A CDK4 APOD
5 immune system MP:0005387 10.43 VEGFA TP53 CDKN2A CDK4 BSG DMBT1
6 cellular MP:0005384 10.42 TP53 PTEN CDKN2A CDK4 VEGFA EGFR
7 behavior/neurological MP:0005386 10.4 TP53 PTEN CDKN2A CDK4 APOD VEGFA
8 hematopoietic system MP:0005397 10.39 TP53 PTEN BSG CDKN2A CDK4 VEGFA
9 endocrine/exocrine gland MP:0005379 10.37 VEGFA TP53 PTEN BSG CDKN2A CDK4
10 digestive/alimentary MP:0005381 10.35 TP53 PTEN VEGFA CDKN2A CDK4 DMBT1
11 neoplasm MP:0002006 10.35 VEGFA TP53 CDK4 CDKN2A DMBT1 EGFR
12 nervous system MP:0003631 10.3 TP53 PTEN CDKN2A CDK4 APOD VEGFA
13 integument MP:0010771 10.29 TP53 PTEN CDKN2A CDK4 VEGFA EGFR
14 muscle MP:0005369 10.27 VEGFA TP53 CDKN2A CDK4 GFAP EGFR
15 embryo MP:0005380 10.25 TP53 PTEN CDKN2A CDK4 VEGFA EGFR
16 liver/biliary system MP:0005370 10.13 TP53 PTEN BSG CDKN2A CDK4 VEGFA
17 no phenotypic analysis MP:0003012 10.13 TP53 CDKN2A VEGFA EGFR CDKN2B MGMT
18 limbs/digits/tail MP:0005371 10.08 TP53 PTEN VEGFA EGFR MDM2 MMP9
19 normal MP:0002873 10.06 TP53 PTEN CDK4 VEGFA EGFR GFAP
20 reproductive system MP:0005389 10.03 VEGFA TP53 PTEN BSG CDKN2A CDK4
21 renal/urinary system MP:0005367 10.02 VEGFA TP53 PTEN CDK4 DMBT1 EGFR
22 pigmentation MP:0001186 9.91 TP53 PTEN CDKN2A CDK4 EGFR MDM2
23 respiratory system MP:0005388 9.9 TP53 PTEN VEGFA BSG CDKN2A EGFR
24 skeleton MP:0005390 9.65 TP53 PTEN CDKN2A VEGFA EGFR MMP2
25 vision/eye MP:0005391 9.32 TP53 PTEN CDKN2A CDK4 VEGFA EGFR

Drugs & Therapeutics for Grade Iii Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 367)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
3
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
5
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85622-93-1 5394
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 4342-03-4 5351166
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
9
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
10
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
13
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
14
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Benzocaine Approved, Investigational Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
17
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
18
Dopamine Approved Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
19
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
20
Cyproheptadine Approved Phase 3 129-03-3 2913
21
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
22
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
23
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
24 tannic acid Approved, Nutraceutical Phase 3,Phase 2,Not Applicable
25
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
27 Semustine Experimental, Investigational Phase 3 13909-09-6
28 Mitolactol Investigational Phase 3 10318-26-0
29 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
30 Dianhydrogalactitol Investigational Phase 3 23261-20-3
31 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
34 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
35 Ether Phase 3,Phase 2,Phase 1
36 Photosensitizing Agents Phase 3,Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
38 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
39 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
40 Antimitotic Agents Phase 3,Phase 1,Phase 2
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
45 Keratolytic Agents Phase 3,Phase 1,Phase 2
46
Cobalt Phase 3 7440-48-4 104729
47 Antibodies Phase 2, Phase 3,Phase 1
48 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
49 Endothelial Growth Factors Phase 2, Phase 3,Phase 1
50 Histone Deacetylase Inhibitors Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 376)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
4 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
5 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
6 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
7 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
8 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
9 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
10 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
11 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
15 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
16 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
17 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
18 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
19 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
20 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
21 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Active, not recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
22 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Not yet recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
23 Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
24 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
25 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
26 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
27 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
28 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
29 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
30 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
31 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
32 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
33 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
34 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
35 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed NCT00301418 Phase 1, Phase 2 Erlotinib
36 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Completed NCT00606008 Phase 2 Sunitinib Malate
37 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
38 Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
39 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) Completed NCT00783393 Phase 2 Temozolomide
40 BNCT to Treat Glioma That Has Progressed Following Radiotherapy Completed NCT00115440 Phase 1, Phase 2
41 Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00004017 Phase 2
42 Combination Chemotherapy for Patients With Brain Cancer Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
43 Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma Completed NCT00409214 Phase 2 LS11 (talaporfin sodium)
44 A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas Completed NCT00921167 Phase 2 Bevacizumab/Irinotecan
45 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
46 Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) Completed NCT00589875 Phase 2 Valacyclovir
47 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
48 Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma Completed NCT00431561 Phase 2 AP 12009 10 µM;AP 12009 80 µM;temozolomide or PCV
49 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
50 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors Completed NCT00003475 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Grade Iii Astrocytoma

Genetic Tests for Grade Iii Astrocytoma

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

41
Brain, Spinal Cord, Bone, Bone Marrow, Liver, T Cells, Endothelial

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

(show top 50) (show all 224)
# Title Authors Year
1
Erratum: Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. ( 29858379 )
2018
2
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. ( 28870792 )
2017
3
Benefit with adjuvant chemotherapy in anaplastic astrocytoma. ( 28801187 )
2017
4
Prognostic value of survivin and DNA topoisomerase III+ in diffuse and anaplastic astrocytomas. ( 28214203 )
2017
5
Crossed Aphasia in a Patient with Anaplastic Astrocytoma of the Non-Dominant Hemisphere. ( 29299104 )
2017
6
Anaplastic astrocytoma with aquaporin-4 positive in CSF: A case report. ( 29390462 )
2017
7
Retinal Metastases From Anaplastic Astrocytoma. ( 28864383 )
2017
8
The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ( 28775924 )
2017
9
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
10
Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiation-Induced Anaplastic Astrocytoma. ( 26185030 )
2016
11
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
12
Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case. ( 27656320 )
2016
13
Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. ( 27864706 )
2016
14
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( 27994066 )
2016
15
Metachronous spinal metastases from supratentorial anaplastic astrocytoma. ( 25767596 )
2015
16
An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma. ( 26337554 )
2015
17
Anaplastic astrocytoma mimicking herpes simplex encephalitis in 13-year old girl. ( 26272584 )
2015
18
Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. ( 25793136 )
2015
19
Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature. ( 26396627 )
2015
20
Chronic Phase Intracranial Hemorrhage Caused by Ruptured Pseudoaneurysm Induced by Carmustine Wafer Implantation for Insulo-opercular Anaplastic Astrocytoma: A Case Report. ( 26423018 )
2015
21
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. ( 25962792 )
2015
22
Somatic BRAF c.1799T&amp;gt;A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. ( 26360803 )
2015
23
Malignant trigeminal nerve sheath tumor and anaplastic astrocytoma collision tumor with high proliferative activity and tumor suppressor p53 expression. ( 25386378 )
2014
24
Value of perfusion weighted magnetic resonance imaging in the diagnosis of supratentorial anaplastic astrocytoma. ( 25368772 )
2014
25
Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination. ( 24368590 )
2014
26
Variability in target delineation for cavernous sinus meningioma and anaplastic astrocytoma in stereotactic radiosurgery with Leksell Gamma Knife Perfexion. ( 25246145 )
2014
27
C-terminally truncated form of I+B-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. ( 24473683 )
2014
28
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. ( 24993250 )
2014
29
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. ( 24395350 )
2014
30
Immediate disappearance of hemifacial spasm after partial removal of ponto-medullary junction anaplastic astrocytoma: case report. ( 25382264 )
2014
31
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent Grade III astrocytoma. ( 23391098 )
2013
32
Anaplastic astrocytoma. ( 23543397 )
2013
33
Parenchymal anaplastic astrocytoma presenting with visual symptoms due to bilateral optic nerve sheath involvement. ( 23838764 )
2013
34
The SDF-1 3'A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors: a study on Iranian anaplastic astrocytoma and glioblastoma multiforme patients. ( 23335032 )
2013
35
An infant with prenatally diagnosed congenital anaplastic astrocytoma who remains disease-free after proton therapy. ( 24015049 )
2013
36
Long-term follow-up of surgical treatment of spinal anaplastic astrocytoma in a cat. ( 23428584 )
2013
37
Heterogeneous nuclear ribonucleoproteins and their interactors are a major class of deregulated proteins in anaplastic astrocytoma: a grade III malignant glioma. ( 23741984 )
2013
38
A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy. ( 24101275 )
2013
39
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). ( 23228988 )
2013
40
Cerebellar anaplastic astrocytoma in an adult with neurofibromatosis type 1: case report and review of literature. ( 23670807 )
2013
41
Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. ( 23526410 )
2013
42
Anaplastic astrocytoma masquerading as hemorrhagic stroke. ( 23510543 )
2013
43
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases. ( 22704562 )
2013
44
Intradural, extramedullary anaplastic astrocytoma arising from the first sacral nerve root. ( 24042468 )
2013
45
The prognosis of anaplastic astrocytoma with radiologic necrosis mimicking glioblastoma. ( 22827635 )
2013
46
Synchronous osteoclastoma and anaplastic astrocytoma: A case report. ( 24179512 )
2013
47
Acquired stuttering due to recurrent anaplastic astrocytoma. ( 24252834 )
2013
48
The genetic landscape of anaplastic astrocytoma. ( 24140581 )
2013
49
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. ( 22821382 )
2012
50
Expression pattern and prognostic significance of IGFBP isoforms in anaplastic astrocytoma. ( 22547392 )
2012

Variations for Grade Iii Astrocytoma

ClinVar genetic disease variations for Grade Iii Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
2 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CDK4 CDKN2A CDKN2B EGFR GFAP MDM2
2
Show member pathways
13.76 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
3
Show member pathways
13.16 CDK4 CDKN2A CDKN2B MDM2 TP53 VEGFA
4
Show member pathways
13.01 CDK4 EGFR MDM2 PDGFRA PTEN TP53
5
Show member pathways
12.81 CDK4 CDKN2A CDKN2B EGFR PTEN TP53
6
Show member pathways
12.77 CDK4 CDKN2A EGFR MDM2 MMP9 PCNA
7
Show member pathways
12.75 EGFR MDM2 PDGFRA PTEN TP53
8
Show member pathways
12.72 CDK4 MDM2 MGMT PCNA TP53
9 12.72 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
10
Show member pathways
12.61 CDK4 MMP9 PCNA PTEN TP53 VEGFA
11
Show member pathways
12.61 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
12
Show member pathways
12.58 EGFR MDM2 MMP2 MMP9 TP53
13 12.55 CDK4 CDKN2A MDM2 MGMT PCNA TP53
14 12.47 CDK4 CDKN2A CDKN2B PCNA PDGFRA TP53
15
Show member pathways
12.46 EGFR MDM2 PDGFRA TP53
16 12.45 CDKN2A EGFR MDM2 MMP9 PDGFRA PTEN
17
Show member pathways
12.43 CDK4 CDKN2A MDM2 PTEN TP53
18 12.4 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
19
Show member pathways
12.37 CDK4 CDKN2A CDKN2B TP53
20
Show member pathways
12.37 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
21 12.34 CDK4 CDKN2A CDKN2B MDM2 TP53
22 12.32 EGFR MDM2 MMP2 MMP9 TP53 VEGFA
23
Show member pathways
12.28 CDK4 MDM2 PTEN TP53
24 12.24 EGFR MMP2 MMP9 TP53 VEGFA
25 12.19 CDK4 CDKN2A CDKN2B MDM2 PTEN TP53
26 12.18 CDK4 EGFR MDM2 PDGFRA PTEN TP53
27
Show member pathways
12.16 EGFR MDM2 MMP2 PTEN
28 12.16 CDK4 EGFR MDM2 PTEN TP53 VEGFA
29 12.13 MMP2 MMP9 TP53 VEGFA
30
Show member pathways
12.13 CDKN2B EGFR MDM2 PTEN
31 12.11 CDKN2A MDM2 MMP2 TP53 VEGFA
32
Show member pathways
12.09 CDK4 EGFR PDGFRA
33
Show member pathways
12.08 MDM2 PCNA PTEN TP53
34 12.07 EGFR MDM2 MMP2 PCNA PTEN TP53
35 12.05 CDK4 EGFR GFAP MMP9 TP53
36 12.04 CDKN2A MDM2 PTEN TP53
37 12.03 MMP2 MMP9 TP53 VEGFA
38 11.98 CDKN2A MDM2 PCNA PTEN TP53
39 11.93 CDK4 CDKN2B PTEN TP53
40 11.89 CDK4 MDM2 PCNA TP53
41 11.87 EGFR MDM2 PTEN
42 11.86 MMP2 MMP9 PDGFRA
43 11.82 GFAP OLIG1 OLIG2 PDGFRA VEGFA
44 11.81 CDK4 MMP9 TP53
45 11.8 CDK4 CDKN2A EGFR MDM2 MGMT PDGFRA
46 11.76 CDKN2A MDM2 TP53
47
Show member pathways
11.76 CDKN2A MDM2 TP53
48 11.74 EGFR PDGFRA PTEN TP53
49 11.71 EGFR MMP2 MMP9
50 11.7 EGFR MMP2 MMP9

GO Terms for Grade Iii Astrocytoma

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 CDKN2A MDM2 PTEN TP53 VEGFA
2 positive regulation of apoptotic process GO:0043065 9.93 CDK4 CDKN2A MMP9 PTEN TP53
3 angiogenesis GO:0001525 9.92 APOD MMP2 PTEN VEGFA
4 multicellular organism development GO:0007275 9.92 CDK4 DMBT1 EGFR OLIG1 OLIG2 PDGFRA
5 positive regulation of cell proliferation GO:0008284 9.91 CDK4 EGFR MDM2 PDGFRA PTEN VEGFA
6 positive regulation of cell migration GO:0030335 9.89 EGFR MMP9 PDGFRA VEGFA
7 extracellular matrix organization GO:0030198 9.88 BSG GFAP MMP9 PDGFRA
8 response to drug GO:0042493 9.88 APOD CDK4 MDM2 MGMT PTEN
9 extracellular matrix disassembly GO:0022617 9.8 BSG MMP2 MMP9
10 protein sumoylation GO:0016925 9.79 CDKN2A MDM2 PCNA
11 epithelial cell differentiation GO:0030855 9.78 DMBT1 PCNA VEGFA
12 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.75 MDM2 PCNA TP53
13 cellular response to amino acid stimulus GO:0071230 9.73 EGFR MMP2 PDGFRA
14 positive regulation of fibroblast proliferation GO:0048146 9.72 CDK4 EGFR PDGFRA
15 positive regulation of DNA replication GO:0045740 9.7 EGFR PCNA PDGFRA
16 embryo implantation GO:0007566 9.69 BSG MMP2 MMP9
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MDM2 MMP2 MMP9
18 replicative senescence GO:0090399 9.63 CDKN2A TP53
19 DNA ligation GO:0006266 9.63 MGMT PCNA
20 cellular response to reactive oxygen species GO:0034614 9.63 EGFR MMP9 PDGFRA
21 amyloid fibril formation GO:1990000 9.6 CDKN2A MDM2
22 cellular response to hypoxia GO:0071456 9.56 MDM2 PTEN TP53 VEGFA
23 negative regulation of apoptotic process GO:0043066 9.56 EGFR MDM2 MGMT MMP9 PDGFRA PTEN
24 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.4 PDGFRA VEGFA
25 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
26 positive regulation of DNA repair GO:0045739 9.33 EGFR MGMT PCNA
27 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.92 CDK4 CDKN2A CDKN2B PTEN

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 CDKN2A CDKN2B EGFR PTEN TP53
2 enzyme binding GO:0019899 9.65 EGFR MDM2 PCNA PTEN TP53
3 identical protein binding GO:0042802 9.56 EGFR GFAP MDM2 MMP9 PCNA PTEN
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.37 CDKN2A CDKN2B
5 disordered domain specific binding GO:0097718 9.33 CDKN2A MDM2 TP53
6 platelet-derived growth factor receptor binding GO:0005161 8.8 PDGFRA PTEN VEGFA

Sources for Grade Iii Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....